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Abstract
Objectives To evaluate the diagnostic performance of
diffusion-weighted imaging (DWI) as a single non-invasive
method in detecting prostate cancer (PCa) and to deduce its
clinical utility.
Methods A systematic literature search was performed to
identify relevant original studies. Quality of included stud-
ies was assessed by QUADAS-2 (Quality Assessment of
Diagnostic Accuracy Studies). Data were extracted to cal-
culate sensitivity and specificity as well as running the test
of heterogeneity and threshold effect. The summary re-
ceiver operating characteristic (SROC) curve was drawn
and area under SROC curve (AUC) served as a determination
of the diagnostic performance of DWI for the detection of
PCa.
Results A total of 21 studies were included, with 27
subsets of data available for analysis. The pooled sen-
sitivity and specificity with corresponding 95 % confi-
dence interval (CI) were 0.62 (95 % CI 0.61–0.64) and
0.90 (95 % CI 0.89–0.90), respectively. Pooled positive
likelihood ratio and negative likelihood ratio were 5.83
(95 % CI 4.61–7.37) and 0.30 (95 % CI 0.23–0.39),
respectively. The AUC was 0.8991. Significant hetero-
geneity was observed. There was no notable publication
bias.
Conclusions DWI is an informative MRI modality in detect-
ing PCa and shows moderately high diagnostic accuracy.
General clinical application was limited because of the ab-
sence of standardized DW-MRI techniques.
Key points
• DWI provides incremental information for the detection and
evaluation of PCa
• DWI has moderately high diagnostic accuracy in detecting
PCa
• Patient condition, imaging protocols and study design pos-
itively influence diagnostic performance
• General clinical application requires optimization of image
acquisition and interpretation
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Introduction
Prostate cancer (PCa) is the most prevalent malignant tumour
among men and the second leading cause of cancer-related
deaths following lung or bronchus cancer. The growing elder-
ly population has led to the highest increase in the number of
estimated new PCa cases [1].
In men with an elevated level of serum prostate-specific
antigen (PSA), the diagnosis of PCa before prostatectomy is
confirmed histologically by performing a transrectal ultra-
sound (TRUS)-guided biopsy. However, the high false-
negative rate of TRUS-guided biopsy is thought to be unac-
ceptable [2], and the poor tolerance of patients to the invasive
procedures is another challenge [3]. Therefore, a non-invasive
method to diagnose prostate cancer with high accuracy is
required.
Various magnetic resonance methods have been investigat-
ed for the detection of PCa. In addition to conventional
anatomic T2-weighted imaging (T2WI), functional MR tech-
niques such as diffusion-weighted imaging (DWI), dynamic
contrast-enhanced imaging (DCE-MRI) and magnetic reso-
nance spectroscopy (MRS) have shown promise in the im-
provement of non-invasive detection of PCa [4–6]. In partic-
ular, DWI is an MR-based technique that probes the function
of tissues. It is sensitive to thermally driven molecular water
motion, which in vivo is impeded by cellular packing, intra-
cellular elements, membranes and macromolecules. Reduced
diffusion of water has been attributed to the increased cellu-
larity of malignant lesion, with reduction of the extracellular
space and restriction of the motion of extracellular water [7,
8]. This approach was initially applied to neurologic disorders
[9]. Recently, numerous studies have been implemented to
characterize abdominal and pelvic lesions [10–12]. Among
them, one of the most promising applications is the detection
of PCa with DWI.
Numerous studies have explored the diagnostic per-
formance of DWI in detecting PCa with widely varied
sensitivity and specificity (29–94 % and 39–100 %,
respectively) [13–33]. Recently, there have been several
meta-analysis articles [34–38] regarding this topic with
slight differences in the pooled results. Therefore, this
study aims to evaluate the diagnostic performance of
DWI in detecting PCa, through a synthesis of a larger
number of published experimental research, and to de-
duce its clinical utility.
Materials and methods
Literature search and screening
A systematic literature search was performed independently by
two investigators in MEDLINE, Web of Science, EMBASE,
SpringerLink and ScienceDirect to identify relevant arti-
cles published before September 2013 by using keywords
of “Diffusion magnetic resonance imaging or diffusion-
weighted imaging or DWI or magnetic resonance imaging
or apparent diffusion coefficient” and “prostate cancer or
prostatic neoplasms or prostate”. The species was defined
as “Humans”. We did not limit our search to publications
from certain nations, but articles published only in English
were identified.
Inclusion criteria were (a) DWI was performed to iden-
tify prostate lesion; (b) sufficient data were available to
calculate true-positive (TP), false-positive (FP), false-
negative (FN) and true-negative (TN) values; (c) all pa-
tients had histopathologic results (biopsy or surgery) as
reference standard; (d) the study population should be no
less than 10. Review articles, abstracts, letters, comments,
guidelines and case reports were excluded as well as
republished studies. Investigators were not blinded to the
information about the authors, the authors’ affiliation or
the journal name.
Data extraction and quality assessment
As decided upon beforehand, we extracted the following
information: patient baseline (study population, age, lev-
el of PSA, Gleason score of cancer lesion, tumour
volume, etc.), study design (prospectively or retrospec-
tively), blinding procedure, reference standard, time in-
terval between index test and reference standard, image
protocols adopted to perform DWI (magnetic field
strength, b values, type of coil and diagnostic threshold)
and the diagnostic results (TP, FP, FN and TN). The
calculation of TP, FP, FN and TN was on a per-lesion or per-
segment basis.
The quality of included studies was assessed according to
QUADAS-2 (Quality Assessment of Diagnostic Accuracy
Studies) [39]. Data extraction and quality assessment were
carried out independently by the same two investigators, and
disagreements were resolved by consensus.
Statistical analysis
The Q statistic of the Chi-square value test and the incon-
sistency index (I2) were used to estimate the heterogeneity
between enrolled studies, and P<0.1 or I2>50 % indicat-
ed the presence of heterogeneity [40]. If notable hetero-
geneity was observed, the diagnostic performance was
summarized by using a random-effects coefficient binary
regression model [41]. The summary receiver operating
characteristic (SROC) curve was constructed and areas
under the SROC curve (AUC) served as the determination
of the diagnostic performance for the detection of PCa
by DWI [42].
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Threshold effect can be recognized visually by noticing a
typical pattern of “shoulder-arm” shape in the ROC plane.
Meanwhile, the Spearman correlation coefficient between the
logit of sensitivity and the logit of (1−specificity) was com-
puted to confirm the existence of threshold effect. A strong
positive correlation with P<0.05 would suggest threshold
effect [43].
Heterogeneity could also be generated from other re-
lated factors. Therefore, meta-regression analysis and sub-
group analysis were used to determine factors that con-
tributed to the heterogeneity and explore how those fac-
tors influence the diagnostic results [44]. In addition, a
sensitivity analysis was performed to ensure the reliability
of included studies. The heterogeneity test, assessment of
threshold effect, diagnostic performance as well as the
meta-regression analysis and subgroup analysis were car-
ried out by Meta-DiSc (version 1.4) [45].
Publication bias was assessed through an asymmetry
test and the Deeks’ funnel plot using Stata (version
12.0). An inverted symmetrical funnel plot with
P>0.05 was considered to indicate the absence of pub-
lication bias [46].
Results
The comprehensive literature search identified 537 articles, of
which 21 [13–33] were eligible and finally included in this study.
Study characteristics and quality assessment
Of the included 21 studies, ten were conducted prospectively,
the remaining 11 retrospectively. MRI reviewer blinding to
other test results and clinical data was reported in 14 studies
and non-blinding in four studies, with another three unclear.
Images were acquired with and without the use of an
endorectal coil in nine and 12 studies, respectively. All pa-
tients had biopsy or surgery results as reference standard.
Eleven studies took biopsy as reference standard, seven stud-
ies took radical prostatectomy as reference standard and the
other three studies took either biopsy or surgery results as
reference standard. The quality of included studies was good.
Quality assessment for all included studies is presented in
Table 1. Figure 1 shows a graphical display for QUADAS-2
results regarding the proportion of studies with low, high or
unclear risk of bias.
Table 1 Quality assessment of the 21 included diagnostic studies















Kumar et al. + + + + + + +
Aydin et al. − − + − + + +
Koo et al. − + + + + + +
Ibrahiem et al. + + + + + + +
Kim et al. − + + + − + +
Yamamura
et al.
+ − + ? + + +
Girometti et al. − ? + + + + +
Selnæs et al. − − + − + + +
Portalez et al. − ? + + − + +
Tamada et al. − + + + + + +
Rinaldi et al. − ? + − + + +
Yagci et al. + + + + + + +
Weidner et al. + + + ? + + +
Kim et al. − − + + + + +
Chen et al. + + + ? + + +
Iwazawa et al. + + + + + + +
Miao et al. + + + + + + +
Isebaert et al. − + + + + + +
Vilanova et al. + + + − + + +
Peng et al. − − + + + + +
Lim et al. − + + + + + +
+ low risk, − high risk, ? unclear risk
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There were a total of 1,204 patients with 820 positive for
cancer enrolled in 21 studies, and their ages ranged from 40 to
87. The PSA level (mean/range, or median if an extreme value
was observed) of each study was recorded, ranging widely
from 0.48 to 1,000 ng/mL. The Gleason score (median/range),
TNM stage and diameter of lesion were also recorded if
available. Principal study and patient characteristics are sum-
marized in Table 2. Methodological and imaging protocol
characteristics related to the diagnostic test are listed in
Table 3.
Cancer was evaluated on a per-lesion or per-segment basis.
A total of 8,448 prostate lesion (2,864 malignant, 5,584 be-
nign) were analysed within 21 studies. Multiple subsets of
data in the same study were counted for the following reasons:
(a) different b values were used to perform DWI; (b) prostate
lesions were assessed in different regions (peripheral, transi-
tion or central zone). Thus, we had 27 subsets of data available
for analysis. Diagnostic results of each subset are presented in
Table 4.
Diagnostic performance
The pooled sensitivity and specificity with corresponding
95 % confidence intervals were 0.62 (95 % CI 0.61–0.64)
and 0.90 (95 % CI 0.89–0.90), respectively. Sensitivity of
individual studies ranged widely from 29 % to 94 %, while
specificity of individual studies ranged from 39 % to 100 %.
According to the SROC curve, the AUC was 0.8991, indicat-
ing a good diagnostic accuracy. Pooled positive likelihood
ratio (PLR) and negative likelihood ratio (NLR) with corre-
sponding 95% confidence intervals were 5.83 (95 % CI 4.61–
7.37) and 0.30 (95%CI 0.23–0.39). Forest plots of sensitivity,
Fig. 1 Graphical display for QUADAS-2 results regarding proportion of
studies with low, high or unclear risk of bias. The results showed that a
high risk of bias existed in patient selection
Table 2 Study and patient characteristics of included studies
Study Publication year Nation Capacity
(Cancer/all)
Age (Years) PSA (Mean/range) Gleason score
(Median/range)
Kumar et al. 2007 India 23/60 64.5 11.04/0.48–1,000 NA
Aydin et al. 2012 Turkey 40/45 69 70.6/1.6–139.53 7/5–10
Koo et al. 2013 Korea 80/80 66 7.16/1.24–56.98 7/6–9
Ibrahiem et al. 2012 Egypt 68/92 65.3 26.3/NA ≥7
Kim et al. 2010 Korea 48/48 66 7.21/2.3–23.2 7/6–9
Yamamura
et al.
2011 Germany 21/50 61.8 7.19/NA 7.13/5–10
Girometti et al. 2012 Italy 5/26 64 5.95/2.52–9.74 6.8/6–9
Selnæs et al. 2012 Norway 36/48 62.2 9.8/4.0–21.4 7.3/6–9
Portalez et al. 2010 France 28/68 62.4 9.16/1.6–25 NA
Tamada et al. 2011 Japan 35/50 70 6.84/4.06–9.94 7/6–10
Rinaldi et al. 2012 Italy 36/41 69 15.15/5.98–133 NA
Yagci et al. 2011 Turkey 21/43 66 9.1/1.4–120 7/6–10
Weidner et al. 2011 Germany 10/16 63.5 NA/4.25–137 NA/6–8
Kim et al. 2007 Korea 35/35 64.3 7.94/1.32–35.3 7/6–8
Chen et al. 2008 China 15/42 63 11.93/4.7–147 <7
Iwazawa et al. 2011 Japan 72/178 68.8 20.51/4.04–568.5 7.04
Miao et al. 2007 Japan 34/37 63.7 22.4/4.07–136 NA
Isebaert et al. 2013 Belgium 75/75 66 10.4/1.5–70.9 7/6–10
Vilanova et al. 2011 Spain 38/70 63.5 7.4/4–17.2 7/5–8
Peng et al. 2013 America 48/48 62.5 7.0/0.8–256 7/6–9
Lim et al. 2009 South Korea 52/52 65 10.5/1.2–79.6 7/6–9
PSA prostate-specific antigen (ng/mL), NA data unavailable
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specificity, PLR and NLR are shown in Fig. 2. The SROC
curve for all 27 subsets of data is shown in Fig. 3.
Heterogeneity assessing and meta-regression analysis
The heterogeneity test of sensitivities and specificities showed
Q=777.24 (p<0.000), I2=96.7 % and Q=320.85 (p<0.000),
I2=91.9 %, respectively. Thus, a highly significant heteroge-
neity was detected.
Threshold effect was eliminated through the ROC plane,
which showed the absence of a “shoulder-arm” shape. Further
analysis showed that the Spearman correlation coefficient
between the logit of sensitivity and the logit of (1−specificity)
was 0.219 (p=0.273), and confirmed that there must be factors
other than threshold effect that result in the notable heteroge-
neity. A single-factor meta-regression analysis showed that
patient condition, magnetic field strength and MRI reviewer
blinding to other test results and clinical data contributed
significantly to the heterogeneity.
Subgroup analysis
Subgroup analysis was performed between different study char-
acteristics. Non-blinding (or unclear) studies and studies about
cancer detection in the peripheral zone yielded the highest sen-
sitivity of 79 % (0.79 [95 % CI 0.74–0.83] and 0.79 [95 % CI
0.75–0.83], respectively). Non-blinding (or unclear) studies
yielded the highest specificity of 93 % (95 % CI 0.91–0.94).
The results of the subgroup analysis are presented in Table 5.
Sensitivity analysis
Among the 21 included studies, the mean level of
serum PSA concentrated was 5.95–26.3 ng/mL, whereas
in the other two studies, the mean level of PSA was
Table 3 Methodological and imaging protocol characteristics regarding the diagnostic test
Study FS (T) De BF RS B TH (×10−3 mm2/s) TI (days) Coil
Kumar et al. 1.5 Pros 0/250/500/750/1,000 1 Y 1.17 <7 B
Aydin et al. 1.5 Pros 0/800 3 Y – 28/? A
Koo et al. 3.0 Retro 0/300/700/1,000/2,000 2 Y LOS-3 34 A
Ibrahiem et al. 1.5 Pros 0/800 1 Y 1.0 16.7 A
Kim et al. 3.0 Retro 0/1,000/2,000 2 Y – 39 A
Yamamura
et al.
1.5 Retro 50/400/800 1 N 1.21 – B
Girometti et al. 3.0 Pros 0/800/1,000 1 UN 0.9 27 A
Selnæs et al. 3.0 Pros 50/300/600/800 2 UN 1.33 5.5 A
Portalez et al. 1.5 Pros 0/600 1 UN 1.24 11 B
Tamada et al. 1.5 Retro – 1 Y – 23 A
Rinaldi et al. 1.5 Pros 0/250/500/750/1,000 3 UN 1.24 – B
Yagci et al. 1.5 Pros 0/800 1 Y 1.2 <7 B
Weidner et al. 1.5 Retro 0/50/150/300/600/800 1 Y LOS-4 – B
Kim et al. 3.0 Pros 0/1,000 2 UN 1.67c
1.61d
16 A
Chen et al. 1.5 Retro 0/1,000 1 Y LOS-4 <90 A
Iwazawa et al. 1.5 Retro 0/1,000 1 Y – 8 A
Miao et al. 3.0 Retro 0/300/600 1 Y LOS-4 <21 A
Isebaert et al. 1.5 Pros 0/50/100/500/750/1,000 2 Y – 16 A
Vilanova et al. 1.5 Retro 0/1,000 3 Y LOS-3 13 B
Peng et al. 1.5 Retro 0/50/200/1,500/2,000a
0/1,000b
2 UN 0.99 34.5 B
Lim et al. 1.5 Retro 0/1,000 2 Y LOS-4 11 B
FS field strength,De design (Pros prospective, Retro retrospective), BF b factor, RS reference standard (1 TRUS-guided biopsy, 2 radical prostatectomy
results, 3 1 or 2), B blind (Y yes, N no, UN unknown), TH threshold (the diagnostic threshold of ADC), LOS level of suspicion (1 definitely no tumor, 2
probably no tumor, 3 equivocal, 4 probably tumor, 5 definitely tumor), TI time intervals, Coil Awithout the use of endorectal coil, Coil Bwith the use of
an endorectal coil
a b values used by 29 patients
b b values used by 24 patients
c Diagnostic threshold for peripheral zone
d Diagnostic threshold for transition zone
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extremely high (70.6 ng/mL) [14] or unknown [25], and
yielded the lowest sensitivity and specificity. Therefore,
we conducted a sensitivity analysis for the 19 studies.
There was no notable threshold effect in the evaluated 19
studies. The pooled weighted sensitivity, specificity, positive
LR and negative LR with corresponding 95 % confidence
intervals were determined to be SEN, 0.63 (95 % CI 0.62–
0.65); SPE, 0.90 (95 % CI 0.89–0.91); PLR, 6.52 (95 % CI
5.23–8.12); NLR, 0.28 (95 % CI 0.21–0.37). The AUC was
0.9120.
Publication bias
The funnel plot shows that studies were distributed symmet-
rically on a scatter plot of diagnostic odds ratio (DOR) against
1/(effective sample size, ESS)1/2. The result of the Deeks’
funnel plot asymmetry test (P=0.67) showed no evidence of
the existence of notable publication bias.
Discussion
PCa is more likely to be diagnosed in patients with advanced
age, especially over the age of 60 [1]. Accurate cancer detec-
tion and evaluation is essential to focal treatment planning
[47]. Diagnosis of PCa with quantitative DWI involves the
apparent diffusion coefficient (ADC), which is lower in PCa
than normal prostate tissue [48]. Previous studies have dem-
onstrated that DWI was a feasible method to detect PCa.
Meanwhile, DWI was also considered to play an important
role in monitoring therapy response, evaluating cancer aggres-
siveness and metastasis, guiding targeted biopsy and patient
follow-up [49]. Nevertheless, all applications referred to
above were based on an accurate diagnosis of PCa.
In this study, we explored the ability of DWI in detecting
PCa. Results showed that for prostate cancer detection, DWI
had high specificity (90 %) and relatively low sensitivity
(62 %). Both sensitivity and specificity showed large
Table 4 Diagnostic results of DWI on a per-lesion or per-segment basis
Study TP FP FN TN SEN (%) SPE (%) Note
Kumar et al. 17 10 6 27 0.74 0.73 PZ
Aydin et al. 34 17 82 77 0.29 0.82
Koo et al. 75 42 130 553 0.37 0.93 b=300
160 49 45 546 0.78 0.92 b=700
174 38 31 557 0.85 0.94 b=1,000
152 22 53 573 0.74 0.96 b=2,000
Ibrahiem et al. 57 10 11 14 0.84 0.58 PZ
Kim et al. 158 49 22 443 0.88 0.9 b=1,000
128 40 52 452 0.71 0.92 b=2,000
Yamamura
et al.
57 17 5 221 0.92 0.93
Girometti et al. 4 14 8 182 0.33 0.93
Selnæs et al. 23 10 8 114 0.74 0.92 PZ
Portalez et al. 16 15 25 352 0.39 0.96 PZ
Tamada et al. 39 11 64 286 0.38 0.96
Rinaldi et al. 42 0 6 9 0.88 1.0
Yagci et al. 58 34 11 155 0.84 0.82 PZ
Weidner et al. 11 11 3 7 0.79 0.39 PZ
Kim et al. 51 6 3 64 0.94 0.91 PZ
9 11 1 59 0.90 0.84 TZ
Chen et al. 42 37 9 164 0.82 0.82
Iwazawa et al. 150 114 34 414 0.82 0.78 PZ
88 109 46 469 0.66 0.81 CZ
Miao et al. 121 29 23 123 0.84 0.81
Isebaert et al. 359 44 617 732 0.37 0.94
Vilanova et al. 37 8 14 81 0.73 0.91
Peng et al. 49 6 12 37 0.8 0.86
Lim et al. 171 57 56 340 0.75 0.86
TP true positive, FP false positive, FN false negative, TN true negative, SEN sensitivity, SPE specificity, PZ peripheral zone, TZ transition zone, CZ
central zone
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Fig. 2 Forest plots of SEN (a), SPE (b), PLR (c) and NLR (d) of DWI in
detecting PCa. TheQ statistics and I2 indexes of sensitivity and specificity
suggested the presence of notable heterogeneity, and the diagnostic
performance was summarized by using a random-effects coefficient
binary regression model
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variability. Next, we focused on the SROC curve, which gave
an AUC of 0.8991 indicating a good, but not excellent,
diagnostic performance. This result was in accordance with
previous studies [34, 35, 37, 38]. Moreover, owing to the larger
Fig. 2 (continued)
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number of original studies and extensive statistical analysis,
results of this study make up for some limitations that previous
studies acknowledged and gave objective and practical sugges-
tions for.
There was significant heterogeneity between the included
studies. To explore the source of heterogeneity, we first elim-
inated threshold effect through the ROC plane. Meta-
regression analysis showed that study population, patient
age, study design, reference standard, diagnostic threshold,
time interval and type of coil did not contribute to the hetero-
geneity statistically. Patient condition, magnetic field strength
and MRI reviewer blinding to other test results and clinical
information were thought to be the most important variable
sources of heterogeneity. The results of sensitivity analysis for
19 studies were similar to the original results, indicating that
the results of this study were reliable.
Detectability of PCa depends on tumour characteristics
including tumour Gleason score, histological volume, archi-
tecture and location [50]. There was greater sensitivity for
tumours of higher grade or larger size [51]. Numerous studies
have suggested strong correlation between Gleason score and
tumour volume and between PSA level and tumour volume
[52, 53]. The level of serum PSA is related to patient condi-
tion, such as tumour volume and progression, and is easily
affected bymultiple factors [54]. In this meta-analysis, tumour
volumewas not described inmuch detail, and the level of PSA
varied widely from 0.48 to 1,000 ng/mL. We performed a
subgroup analysis between studies with the mean PSA<
20 ng/mL and ≥20 ng/mL. Table 5 shows that patients with
high PSA level had higher sensitivity and relatively low
specificity when diagnosed with DWI. Meanwhile, the Q
statistics and I2 decreased significantly within the two
subgroups, especially the high PSA group. No significant
difference was found in the mean Gleason score between the
two groups. Further investigation of tumour characteristics
was limited because data on a per-patient basis were required.
Therefore, we suggest that large-scale, quality-controlled
studies specifically addressing those factors should be con-
ducted in the future.
In the subgroup analysis, we compared the effect of two
magnetic field strengths, 3.0T and 1.5T. High field strength
(3.0T) demonstrated high sensitivity and specificity for the
detection of PCawith DWI (Table 5). Prostate imaging at 3.0T
benefits from higher signal-to-noise ratio (SNR), and enables
either an increased spatial resolution or an increase in SNR of
the ADC maps [55]. For this reason, improvements in the
localization and detection of PCa were expected [26, 56, 57].
However, some studies [58, 59] reported that DWI performed
at 3.0T generally had similar ADC values, but worse image
quality compared with 1.5T, suggesting that there was no
significant advantage for the diagnosis of PCa by 3-T MRI
over 1.5-T MRI. Therefore, to take full advantage of the
benefits of high field strength, improved acquisition tech-
niques are required.
There are as yet no standardized DW-MRI techniques, and
a large variety of imaging parameters exist for DWI in the
number and size of b values, diagnostic threshold and coils.
Performing DWI requires at least two b factors which allows
for the calculation of ADC. High b value permits high diffu-
sion weighting, and tumour tissue often has higher signal
intensity or lower ADC values on ADC maps compared with
native tissue [60]. The typical b value for prostate imaging
varies in the range 0–1,500 s/mm2. Some studies [61, 62]
suggested that the use of b=2,000 s/mm2 is diagnostically
Fig. 3 Summary receiver
operating characteristic (SROC)
curve for DWI in detecting PCa.
The AUC was 0.8991, indicating
a good diagnostic accuracy but
not excellent
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superior to that of b=1,000 s/mm2. However, other studies
[15, 17] reported that for predicting PCa, the optimal b value
for 3.0-T DWI was 1,000 s/mm2. A recent study also sug-
gested the use of the true diffusion coefficient, which can be
obtained using a minimum of three b values and is less
influenced than the ADC by b value selection [63]. In this
meta-analysis, there was profound discrepancy in the choice
of b values between individual studies, ranging from 0 to
2,000 s/mm2. We failed to analyse the potential influence of
different b values because three or more b values (median, 3
values/study; range, 2–6) were used to acquire different dif-
fusion weighting in the same study. Moreover, the consider-
able overlap of ADC between cancer and noncancerous tissue
made it difficult to determine a diagnostic threshold [64, 65].
Besides, the level of suspicion (LOS) was estimated in six
studies [15, 25, 27, 29, 31, 33] for qualitative interpretation of
DWI results, which made a uniformed image interpretation
even harder. In brief, all those challenges prompted further
optimization of image acquisition and interpretation.
An endorectal coil provides a superior SNR compared with
a pelvic phased array coil but causes the displacement of the
prostate gland, reduced patient compliance and increased
susceptibility artefacts [66, 67]. The subgroup analysis results
showed that for the detection of PCa, sensitivity of DWI with
an endorectal coil used was significantly higher (0.77 [95 %
CI 0.73–0.80]) than without an endorectal coil (0.60 [95 % CI
0.58–0.61]). Therefore, although the overall diagnostic accu-
racy was not improved, the use of an endorectal coil was
recommended for increased sensitivity.
The subgroup analysis also found that studies which took
radical prostatectomy as reference standard had a slight im-
provement in specificity, while sensitivity dropped dramati-
cally from 73 % to 59 % compared with studies that took
prostate biopsy as reference standard. We speculated that this
might be caused by the high false-negative rate of prostate
biopsy [2]. Over the last few years, lots of effort has been
made on the optimization of initial prostate biopsy in clinical
practice, and inherent within those optimizations is variation
of the core number, location, labelling and processing for
pathological evaluation [68–72]. To date, there is no consen-
sus in this regard. New imaging methods that allow targeted
biopsy (such as MRI-guided biopsy) were reported to be
possible and improve the assessment of true tumour aggres-
siveness [73]. Hopefully, with the development of new imag-
ing methods, we expect the role of prostate biopsy in the
diagnosis of PCa to be near to perfect.
Furthermore, given the fact that about 70–75 % cancer
arise in the peripheral zone (PZ), we guessed that a separate
imaging protocol specific to PZ tumours might lead to more
accurate diagnosis, because tumours arising in the PZ tend to
Table 5 Results of subgroup analysis









Total 27 0.62 (0.61–0.64) 0.90 (0.89–0.90) 5.83 (4.61–7.37) 0.30 (0.23–0.39) 0.8991
PSA 0.0003
PSA<20 21 0.61 (0.59–0.62) 0.92 (0.91–0.93) 7.57 (6.17–9.29) 0.28 (0.21–0.38) 0.9348
PSA≥20 5 0.70 (0.66–0.73) 0.80 (0.78–0.82) 3.08 (2.35–4.04) 0.35 (0.16–0.73) 0.8326
Field strength 0.0155
1.5T 16 0.55 (0.53–0.57) 0.87 (0.86–0.88) 4.46 (3.42–5.83) 0.34 (0.25–0.46) 0.8616
3.0T 11 0.74 (0.71–0.76) 0.92 (0.91–0.93) 8.42 (6.40–11.07) 0.25 (0.15–0.41) 0.9497
Blinding 0.0872
Blind 19 0.61 (0.59–0.62) 0.89 (0.88–0.90) 5.23 (3.98–6.87) 0.32 (0.24–0.44) 0.8744
Non-blind or unclear 8 0.79 (0.74–0.83) 0.93 (0.91–0.94) 8.55 (6.51–11.23) 0.22 (0.11–0.45) 0.9565
Design 0.2521
Prospective 11 0.46 (0.44–0.49) 0.91 (0.90–0.92) 4.84 (3.29–7.11) 0.38 (0.27–0.52) 0.8908
Retrospective 16 0.73 (0.71–0.75) 0.89 (0.88–0.90) 6.47 (4.78–8.76) 0.27 (0.20–0.38) 0.9003
Reference standard 0.3348
Biopsy 12 0.73 (0.70–0.76) 0.85 (0.84–0.87) 4.28 (3.21–5.70) 0.33 (0.23–0.48) 0.8609
Prostatectomy 15 0.59 (0.57–0.61) 0.92 (0.91–0.93) 7.52 (5.74–9.84) 0.28 (0.19–0.40) 0.9515
Coil 0.9061
Without endorectal coil 18 0.60 (0.58–0.61) 0.90 (0.89–0.91) 6.12 (4.62–8.10) 0.32 (0.23–0.43) 0.9100
With endorectal coil 9 0.77 (0.73–0.80) 0.89 (0.87–0.90) 5.24 (3.26–8.43) 0.27 (0.18–0.41) 0.8820
Location 0.2664
Peripheral zone 8 0.79 (0.75–0.83) 0.85 (0.82–0.86) 4.13 (2.70–6.33) 0.28 (0.17–0.47) 0.8680
No number of data subsets, LR likelihood ratio, AUC area under the curve, P the p value of meta-regression analysis
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be more aggressive [74, 75]. Thus, we analysed the diagnostic
performance of DWI in detecting peripheral zone PCa alone
within eight studies [13, 16, 20, 21, 24–26, 28]. The pooled
sensitivity and specificity were 0.79 (95 % CI 0.75–0.83) and
0.85 (95 % CI 0.82–0.86), respectively. Sensitivity was sig-
nificantly high in detecting peripheral zone PCa compared
with all regions evaluated together (sensitivity 62 %).
However, the overall diagnostic accuracy was not improved
as expected compared with the original results (AUC 0.8991).
It was worth noting that there was still significant heteroge-
neity between these eight studies. Therefore, this conclusion
remains to be confirmed by further investigation and should
be considered with caution.
There are still many challenges in the diagnosis of PCa.
The current pathway for men suspected of having PCa
results in overdiagnosis and overtreatment, as well as
systematically missed significant tumours in the anterior
and apical parts of prostate gland [76]. Additionally, tu-
mours located in the transition zone are more challenging
to detect [77]. Although many MR imaging methods
(T2WI, DWI, DCE-MRI and MRS) have been explored
in the detection of PCa, they all have substantial limita-
tions [78]. Therefore, the combined use of DWI with
T2WI, DCE-MRI or MRS was recommended [79].
We should acknowledge some limitations of this meta-
analysis. First, although a comprehensive literature search
was performed in several authoritative databases, neglecting
a grey literature search and non-English-language articles
might have introduced potential publication bias. Second,
the image interpretation of DWI was performed for the most
part qualitatively, and in many studies blinding was either
unclear or absent. In the subgroup analysis, studies designed
without (or unclear) MRI reviewer blinding to other infor-
mation yielded higher results for both sensitivity and spec-
ificity compared with studies which were designed blinded.
Therefore, an objective interpretation of image results was
queried. Third, although QUADAS was adopted to ensure
high quality of included articles, there were still many
retrospective studies, and many participants in the included
studies were diagnosed or suspected of prostate cancer on
the basis of ultrasound, CTor other clinical information, and
therefore might have caused patient selection bias (Fig. 1)
and a greater sensitivity, which was confirmed by the sub-
group analysis results.
In conclusion, our meta-analysis showed that DWI was an
informative MRI modality and had moderately high diagnos-
tic accuracy for the detection of PCa. Further application of
DWI in detecting PCa requires the optimization of image
acquisition techniques and interpretation.
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